Jessica Jacob1,2, Trevor Goodyear1,3, Pierre-Julien Coulaud1,2, Peter Hoong1,2, Lianping Ti1,2, Rod Knight4,5. 1. British Columbia Centre on Substance Use, 400-1045 Howe St, Vancouver, V6Z 2A9, BC, Canada. 2. Department of Medicine, University of British Columbia, Vancouver, Canada. 3. School of Nursing, University of British Columbia, Vancouver, Canada. 4. British Columbia Centre on Substance Use, 400-1045 Howe St, Vancouver, V6Z 2A9, BC, Canada. bccsu-rk@bccsu.ubc.ca. 5. Department of Medicine, University of British Columbia, Vancouver, Canada. bccsu-rk@bccsu.ubc.ca.
Abstract
OBJECTIVES: People who inject drugs (PWID) are disproportionately impacted by hepatitis C virus (HCV). Despite the availability and efficacy of direct-acting antiviral (DAA) HCV therapies, treatment rates remain low among PWID. Among PWID, those who are young (under age 30) experience high rates of HCV and also face distinct barriers to care. The objective of this study is to identify facilitators and barriers to navigating various facets of the HCV cascade of care, including DAA treatment access, among young PWID. METHODS: We draw on data from in-depth, semi-structured interviews conducted between May and November 2019 with a sample of 11 young, street-involved PWID who have lived experience of HCV and who live in Metro Vancouver, Canada. Informed by a social constructivist epistemology, data were thematically analyzed using an equity-oriented theoretical framework. RESULTS: Our analysis yielded two key themes. First, participants described facilitators to HCV care access, including individual factors (e.g., desire to be cured, knowledge of side effects) and healthcare and socio-contextual factors (e.g., peer supports, supportive youth-specific services). Second, participants described a contrasting set of barriers to HCV care access, including concerns over treatment side effects and (in)eligibility, complex healthcare system navigation, substance use- and housing-related stigma, and clinician gatekeeping of DAAs. CONCLUSION: Findings from this study underscore the need for HCV-related knowledge-building efforts among young PWID and clinicians. Also needed are structural policy interventions to facilitate access to DAAs, including anti-stigma efforts, access to safe housing, and the scale-up of low-barrier youth-specific services and decentralized HCV care.
OBJECTIVES: People who inject drugs (PWID) are disproportionately impacted by hepatitis C virus (HCV). Despite the availability and efficacy of direct-acting antiviral (DAA) HCV therapies, treatment rates remain low among PWID. Among PWID, those who are young (under age 30) experience high rates of HCV and also face distinct barriers to care. The objective of this study is to identify facilitators and barriers to navigating various facets of the HCV cascade of care, including DAA treatment access, among young PWID. METHODS: We draw on data from in-depth, semi-structured interviews conducted between May and November 2019 with a sample of 11 young, street-involved PWID who have lived experience of HCV and who live in Metro Vancouver, Canada. Informed by a social constructivist epistemology, data were thematically analyzed using an equity-oriented theoretical framework. RESULTS: Our analysis yielded two key themes. First, participants described facilitators to HCV care access, including individual factors (e.g., desire to be cured, knowledge of side effects) and healthcare and socio-contextual factors (e.g., peer supports, supportive youth-specific services). Second, participants described a contrasting set of barriers to HCV care access, including concerns over treatment side effects and (in)eligibility, complex healthcare system navigation, substance use- and housing-related stigma, and clinician gatekeeping of DAAs. CONCLUSION: Findings from this study underscore the need for HCV-related knowledge-building efforts among young PWID and clinicians. Also needed are structural policy interventions to facilitate access to DAAs, including anti-stigma efforts, access to safe housing, and the scale-up of low-barrier youth-specific services and decentralized HCV care.
Authors: Brendan Jacka; Tanya Applegate; Art F Poon; Jayna Raghwani; P Richard Harrigan; Kora DeBeck; M-J Milloy; Mel Krajden; Andrea Olmstead; Jeffrey B Joy; Brandon D L Marshall; Kanna Hayashi; Oliver G Pybus; Viviane Dias Lima; Gkikas Magiorkinis; Julio Montaner; Francois Lamoury; Gregory J Dore; Evan Wood; Jason Grebely Journal: J Hepatol Date: 2016-02-26 Impact factor: 25.083
Authors: Sofia R Bartlett; Amanda Yu; Nuria Chapinal; Carmine Rossi; Zahid Butt; Stanley Wong; Maryam Darvishian; Mark Gilbert; Jason Wong; Mawuena Binka; Maria Alvarez; Mark Tyndall; Mel Krajden; Naveed Z Janjua Journal: Liver Int Date: 2019-09-20 Impact factor: 5.828
Authors: Rozalyn Milne; Morgan Price; Bruce Wallace; Anne Drost; Irene Haigh-Gidora; Frank A Nezil; Chris Fraser Journal: Int J Drug Policy Date: 2015-07-21
Authors: Oluwaseun Falade-Nwulia; Paul Sacamano; Sean D McCormick; Cui Yang; Greg Kirk; David Thomas; Mark Sulkowski; Carl Latkin; Shruti H Mehta Journal: Int J Drug Policy Date: 2020-03-02